SEC Form 4 · accession 0001144204-15-006842
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scot Harper
Officer — VP of CLINICAL OPERATIONS
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 8:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 4, 2015 | A | 8,750 | $0.00 | A | 16,250 | D | |
| Common StockF2 | Feb 6, 2015 | F | 693 | $5.14 | D | 15,557 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $5.10 | Feb 4, 2015 | A | 52,500 | A | — | Feb 4, 2025 | Common Stock | 52,500 | 52,500 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/3 annually over a period of 3 years beginning on February 4, 2016, in the form of one share of common stock for each restricted stock unit.
- F2Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 1,875 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2015.
- F3Shares subject to the option vest 1/3 annually over a period of 3 years beginning on February 4, 2016.